The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice
Lynn W Maines, Cecelia L Green, Staci N Keller, Leo R Fitzpatrick, Charles D Smith Apogee Biotechnology Corporation, Hummelstown, PA, USACorrespondence: Charles D Smith, Apogee Biotechnology Corporation, 1214 Research Blvd, Suite 2015, Hummelstown, PA, 17036, USA, Email cdsmith@apogee-biotech.comInt...
Main Authors: | Maines LW, Green CL, Keller SN, Fitzpatrick LR, Smith CD |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-11-01
|
Series: | International Journal of Nephrology and Renovascular Disease |
Subjects: | |
Online Access: | https://www.dovepress.com/the-sphingosine-kinase-2-inhibitor-opaganib-protects-against-acute-kid-peer-reviewed-fulltext-article-IJNRD |
Similar Items
-
Recent Progress in the Development of Opaganib for the Treatment of Covid-19
by: Smith CD, et al.
Published: (2022-07-01) -
Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy
by: Lynn W. Maines, et al.
Published: (2022-10-01) -
The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy
by: Lynn W. Maines, et al.
Published: (2024-02-01) -
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts
by: Faizal Z. Asumda, et al.
Published: (2024-03-01) -
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy
by: Lynn W. Maines, et al.
Published: (2023-11-01)